{"id":"levodopa-carbidopa-intestinal-gel","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dyskinesia"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Peripheral edema"},{"rate":null,"effect":"Infection at infusion site"}]},"_chembl":{"chemblId":"CHEMBL1200748","moleculeType":"Small molecule","molecularWeight":"244.25"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Levodopa is converted to dopamine in the brain to replace depleted neurotransmitter levels in Parkinson's disease. Carbidopa is a decarboxylase inhibitor that prevents premature conversion of levodopa to dopamine in the periphery, allowing more levodopa to reach the brain. Intestinal gel delivery provides continuous, steady-state absorption, reducing motor fluctuations and \"off\" periods experienced with oral dosing.","oneSentence":"Levodopa-carbidopa intestinal gel delivers dopamine precursor (levodopa) directly to the small intestine via continuous infusion, bypassing gastric degradation and improving motor symptom control in advanced Parkinson's disease.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:18:43.678Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced Parkinson's disease with motor fluctuations inadequately controlled by oral levodopa-carbidopa"}]},"trialDetails":[{"nctId":"NCT07151378","phase":"PHASE3","title":"Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease","status":"RECRUITING","sponsor":"University Hospital Tuebingen","startDate":"2025-10-27","conditions":"PARKINSON DISEASE (Disorder)","enrollment":150},{"nctId":"NCT07313176","phase":"","title":"Long Term Effectiveness of Levodopa-Entacapone-Carbidopa Intestinal Gel in Participants With Advanced Parkinson's Disease","status":"RECRUITING","sponsor":"Britannia Pharmaceuticals Ltd.","startDate":"2026-01","conditions":"Advanced Parkinson Disease","enrollment":215},{"nctId":"NCT05043103","phase":"","title":"Long-Term Observational Study on Effectiveness and Safety of Lecigon in Patients With Advanced Parkinson's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Britannia Pharmaceuticals Ltd.","startDate":"2021-07-06","conditions":"Advanced Parkinson Disease","enrollment":312},{"nctId":"NCT06432309","phase":"NA","title":"Opicapone as Adjunctive Therapy to Levodopa-Carbidopa Intestinal Gel in Parkinson's Disease","status":"COMPLETED","sponsor":"University Hospital of Ferrara","startDate":"2022-07-01","conditions":"Parkinson Disease, Effect of Drug","enrollment":22},{"nctId":"NCT02480803","phase":"PHASE4","title":"INfusion VErsus STimulation in Parkinson's Disease","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2014-12-19","conditions":"Parkinson's Disease","enrollment":51},{"nctId":"NCT02604914","phase":"PHASE1","title":"A Sequential Two-Part, Open-Label Study in Healthy Male and Female Subjects","status":"COMPLETED","sponsor":"NeuroDerm Ltd.","startDate":"2015-05-29","conditions":"Parkinson's Disease","enrollment":36},{"nctId":"NCT02549092","phase":"PHASE3","title":"A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-10-26","conditions":"Advanced Parkinson's Disease","enrollment":89},{"nctId":"NCT04500106","phase":"","title":"Study to Assess Participant/Caregiver/Investigator Satisfaction of Video-Assisted Telenursing in Adult Participants With Parkinson's Disease Treated With Levodopa-Carbidopa Intestinal Gel","status":"COMPLETED","sponsor":"AbbVie","startDate":"2021-04-22","conditions":"Parkinson's Disease","enrollment":41},{"nctId":"NCT00660673","phase":"PHASE3","title":"Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2009-11-13","conditions":"Advanced Parkinson's Disease","enrollment":262},{"nctId":"NCT02611713","phase":"","title":"Observational Study Evaluating Long-Term Effectiveness of Duodopa/Duopa in Patients With Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-01-04","conditions":"Advanced Parkinson's Disease","enrollment":213},{"nctId":"NCT01736176","phase":"PHASE3","title":"A Study to Assess the Safety and Efficacy of Levodopa-carbidopa Intestinal Gel (LCIG) for the Treatment of Non-motor Symptoms in Patients With Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2013-03","conditions":"Advanced Parkinson's Disease","enrollment":39},{"nctId":"NCT02485600","phase":"","title":"Observational Study Evaluating Long-term Health Outcomes of Canadian DUODOPA-treated Patients","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-10-19","conditions":"Parkinson Disease (PD)","enrollment":88},{"nctId":"NCT02082249","phase":"PHASE3","title":"An Extension Study to Assess the Safety, Tolerability and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medications","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-03-10","conditions":"Advanced Parkinson's Disease","enrollment":30},{"nctId":"NCT02381444","phase":"","title":"Health Related Quality of Life in LCIG Patients and LCIG Eligible Patients Continuing Oral Therapy","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-04-17","conditions":"Parkinson's Disease (PD)","enrollment":136},{"nctId":"NCT02799381","phase":"PHASE3","title":"A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-02-09","conditions":"Parkinson's Disease (PD)","enrollment":63},{"nctId":"NCT03362879","phase":"","title":"COmedication Study Assessing Mono- and cOmbination Therapy With Levodopa-carbidopa inteStinal Gel","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-12-14","conditions":"Parkinson's Disease (PD)","enrollment":412},{"nctId":"NCT02289729","phase":"","title":"Patient- and Caregiver-reported Symptoms and Outcomes With Levodopa/Carbidopa Intestinal Gel for the Treatment of Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-10","conditions":"Parkinson's Disease","enrollment":62},{"nctId":"NCT01754129","phase":"","title":"Global REsponsE During iNFusIon of a gEl With LevoDopa/Carbidopa","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-12","conditions":"Parkinson's Disease","enrollment":148},{"nctId":"NCT03602924","phase":"","title":"Long-term Safety and Effectiveness of Levodopa-carbidopa Intestinal Gel Infusion","status":"UNKNOWN","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2008-12-01","conditions":"Parkinson Disease","enrollment":40},{"nctId":"NCT01960842","phase":"PHASE3","title":"A Study to Assess the Efficacy, Safety and Tolerability of ABT-SLV187 Monotherapy in Subjects With Advanced Parkinson's Disease (PD) and Persistent Motor Complications, Despite Optimized Treatment With Available Anti-Parkinsonian Medications","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-10","conditions":"Advanced Parkinson's Disease","enrollment":31},{"nctId":"NCT01484990","phase":"PHASE1","title":"A Pharmacokinetic Study of Levodopa and Carbidopa Intestinal Gel in Subjects With Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2010-04","conditions":"Parkinson Disease","enrollment":19},{"nctId":"NCT00141518","phase":"PHASE4","title":"Long-term Study of Duodopa (Levodopa/Carbidopa) in Advanced Parkinson's: Health Outcomes & Net Economic Impact","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2006-03","conditions":"Advanced Idiopathic Parkinson's Disease","enrollment":77},{"nctId":"NCT02448914","phase":"PHASE1","title":"A Study to Compare Plasma Levels of Levodopa, Carbidopa and Entacapone After TRIGEL or Duodopa Infusion in PD Patients","status":"COMPLETED","sponsor":"LobSor Pharmaceuticals AB","startDate":"2015-05","conditions":"Parkinson's Disease","enrollment":11},{"nctId":"NCT01479127","phase":"PHASE2","title":"Study of Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-10","conditions":"Advanced Parkinson's Disease","enrollment":8},{"nctId":"NCT01956032","phase":"","title":"Duodopa Home Titration Using Telemedicine: Evaluation of Use of Resources","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-09","conditions":"Parkinson's Disease","enrollment":15},{"nctId":"NCT00360568","phase":"PHASE3","title":"Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2009-06","conditions":"Dyskinesias, Parkinson's Disease, Severe Motor Fluctuations","enrollment":62},{"nctId":"NCT00335153","phase":"PHASE3","title":"Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2008-01","conditions":"Advanced Parkinson's Disease","enrollment":354},{"nctId":"NCT00357994","phase":"PHASE3","title":"Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2009-01","conditions":"Advanced Parkinson's Disease","enrollment":36},{"nctId":"NCT00660387","phase":"PHASE3","title":"Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2009-12","conditions":"Advanced Parkinson's Disease","enrollment":35},{"nctId":"NCT00906828","phase":"PHASE4","title":"Pharmacokinetics of Levodopa/Carbidopa Infusion With and Without Oral Catechol-O-methyl Transferase (COMT) Inhibitors","status":"COMPLETED","sponsor":"Uppsala University","startDate":"2008-10","conditions":"Parkinson Disease","enrollment":10},{"nctId":"NCT00888186","phase":"PHASE4","title":"Different Dyskinesias in Parkinson's Disease and Their Relation to Levodopa Pharmacokinetics","status":"COMPLETED","sponsor":"Uppsala University","startDate":"2008-02","conditions":"Parkinson Disease, Dyskinesias","enrollment":5}],"_emaApprovals":[],"_faersSignals":[{"count":3,"reaction":"ABDOMINAL PAIN"},{"count":3,"reaction":"CONSTIPATION"},{"count":3,"reaction":"DEHYDRATION"},{"count":3,"reaction":"ILEUS PARALYTIC"},{"count":3,"reaction":"PNEUMONIA"},{"count":3,"reaction":"VOMITING"},{"count":2,"reaction":"CONFUSIONAL STATE"},{"count":2,"reaction":"HYPONATRAEMIA"},{"count":2,"reaction":"PARKINSONISM HYPERPYREXIA SYNDROME"},{"count":2,"reaction":"TOXIC ENCEPHALOPATHY"}],"_approvalHistory":[],"publicationCount":459,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ABT-SLV187","LCIG","Duodopa","Duopa","Carbidopa-levodopa enteral suspension (CLES)"],"phase":"phase_3","status":"active","brandName":"Levodopa-carbidopa intestinal gel","genericName":"Levodopa-carbidopa intestinal gel","companyName":"AbbVie","companyId":"abbvie","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Levodopa-carbidopa intestinal gel delivers dopamine precursor (levodopa) directly to the small intestine via continuous infusion, bypassing gastric degradation and improving motor symptom control in advanced Parkinson's disease. Used for Advanced Parkinson's disease with motor fluctuations inadequately controlled by oral levodopa-carbidopa.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}